First-Line and Neoadjuvant Immunotherapy for Gastric Cancer

Launched by QILU HOSPITAL OF SHANDONG UNIVERSITY · Dec 10, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a type of treatment called immunotherapy for patients with advanced gastric cancer, which is a serious condition where cancer has spread or is very localized. The study aims to see how well these immune-based treatments work as a first-line option or before surgery, while also exploring certain biological markers that might help us understand which patients benefit the most from this therapy. The trial is currently recruiting participants, and anyone aged 18 or older with advanced gastric cancer who hasn’t had any previous cancer treatments can consider joining.

To be eligible, participants should be in relatively good health, with a performance status that indicates they can carry out daily activities. However, those with certain health issues, like a history of severe infections or autoimmune diseases, are not able to join the study. If you participate, you will receive regular monitoring and care while receiving the immunotherapy treatment, and the study will help provide important information about its safety and effectiveness. This could be an opportunity to contribute to important research that may improve future treatment for gastric cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age 18 years old or above
• • 2. Patients with advanced gastric cancer or locally advanced gastric cancer
• • 3. Have not received any previous anti-tumor therapy
• • 4. Patients expected to receive immunotherapy for first-line or neoadjuvant therapy
• • 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
• • 6. Adequate organ function
• Exclusion Criteria:
• • 1. Patients with contraindications to immunotherapy
• • 2. Have received anti-tumor treatments such as immunotherapy and chemotherapy
• • 3. Have a history of active immune deficiency or autoimmune diseases, including HIV positive test, or have other acquired or congenital immune deficiency diseases, or have a history of organ transplantation or autoimmune diseases
• • 4. Severe chronic or active infection requires systemic antibacterial, antifungal, or antiviral treatment, including tuberculosis infection. Have a history of active tuberculosis infection ≥ 1 year before recruitment should also be excluded, unless proved has been completed appropriate treatment
• • 5. History of allogeneic stem cell transplantation or organ transplantation